# International Journal of Engineering Research and Science & Technology

IJERST

ISSN : 2319-5991



www.ijerst.com

Email: editor@ijerst.com or editor.ijerst@gmail.com

International Journal of Engineering Research and Science & Technology

ISSN 2319-5991 www.ijerst.com

https://doi.org/10.62643/ijerst.2025.v21.i2.pp756-762

Vol. 21, Issue 2, 2025

# DEEPSIDE: ENHANCING DRUG SIDE EFFECT PREDICTION WITH DEEP LEARNING

[1]K. Priyanka, MCA Student, Department of MCA

[2] Dr. Dhanaraj Cheelu, Ph.D, Professor, Department of MCA

[12]Dr KV Subba Reddy Institute of Technology, Dupadu, Kurnool

**ABSTRACT**

Unexpected adverse effects during clinical trials may cause drug failures, endangering the participants' health and causing large financial losses. The creation of novel medications may be guided by algorithms that forecast adverse effects. The LINCS L1000 dataset provides a plethora of information on cell line gene expression that has been impacted by different drugs and lays the groundwork for understanding context-specific traits. The state-of-the-art approach, which aims to employ context-specific information, only uses the high-quality experiments in LINCS L1000 and discards a large portion of the trials. Our goal in this study is to use this data to its fullest potential in order to maximise prediction performance. Our experiments involve five deep learning architectures. We find that among multi-layer perceptron-based designs, a multi-modal architecture provides the best prediction performance when drug chemical structure (CS) and the whole set of drug changed gene expression profiles (GEX) are used as modalities. Overall, we discover that the CS offers more details than the GEX. A convolutional neural network-based model that only uses the SMILES string representation of the drugs produces the greatest results; it beats the state-of-the-art by 13:0% macro-AUC and 3:1% micro-AUC. We also show that the model can predict drug-side effect pairings that are mentioned in the literature but are not present in the ground truth side effect dataset.

## I. INTRODUCTION

Computational methods hold great promise for lowering the cost and health risks related to drug development as they may detect possible side effects before clinical trials start. Several learning-based approaches have been developed to predict drug side effects using a range of features, such as drug chemical structures [25, 1, 23, 8, 19, 34, 17, 9, 2, 5], drug-protein interactions [35, 33, 8, 19, 34, 17, 37, 2, 15, 36], protein-protein interactions (PPI) [8, 9], metabolic network activity [38, 26], pathways, phenotype data, and gene annotations [8]. Recently, deep learning models have also been used to predict side effects in addition to the previously mentioned techniques: (i) [31] compares the effectiveness of side effect prediction using different chemical fingerprints extracted using deep architectures, and (ii) [4] uses drug-specific biological, chemical, and semantic information in addition to clinical notes and case reports.

While these methods have demonstrated potential in predicting adverse drug reactions (ADRs, also referred to as drug side effects), the features they use are solely reliant on outside drug knowledge (e.g., drug-protein interactions) and are not condition- or cell-specific (e.g., dosage). Wang et al. (2016) tackle this issue using information from the LINCS L1000 project [32]. This project investigates the changes in gene expression that take place in a number of human cell lines after administration of a wide variety of drugs and small-molecule compounds. Using the gene expression patterns of the treated cells, [32] provides the first comprehensive, unbiased, and reasonably priced prediction of ADRs. The paper formulates the problem as a multi-label classification assignment. Their results suggest that context-dependent information from the gene expression

International Journal of Engineering Research and Science & Technology
ISSN 2319-5991 www.ijerst.com
https://doi.org/10.62643/ijerst.2025.v21.i2.pp756-762
Vol. 21, Issue 2, 2025

profiles might be useful for the side-effect prediction task. The LINCS dataset has a total of 473,647 tests for 20,338 compounds; however, their method reduces noise by using just the highest quality trial for each drug. Given that most of the expression data are left unused, this implies that there could be room for improvement in the prediction performance. Additionally, their technology does feature engineering by converting gene expression characteristics into biological term enrichment vectors. In this work, we investigate whether, without feature engineering, including gene expression data with drug structural data might improve the performance of a deep learning system.

In this study, we propose Deep Side, a deep learning framework for ADR prediction. Deep Side uses just two sources: (i) in vitro gene expression profiling studies (GEX) and related experimental meta data (e.g., dosage and cell line-META); and (ii) the chemical structures of the drugs (CS). Our models are trained on the whole LINCS L1000 dataset, with the SIDER dataset acting as the ground truth for drug-ADR pair labelling [13]. Our experiments include five different designs: a multi-layer perceptron (MLP), an MLP with residual connections (Res MLP), multi-modal neural networks (MMNN. Concat and MMNN. Sum), an MTNN multi-task neural network, and finally a SMILES convolutional neural network (SMILES Conv).

We provide a detailed study of the previously described designs and investigate the relative contributions of different features. Our study shows that CS is a good predictor of negative consequences. The basic MLP model, which utilises CS features as input, improves the state-of-the-art results provided in [32], which uses both GEX (high quality) and CS features, by _11% macro-AUC and _2% micro-AUC. The multi-modal neural network model (MMNN. Sum), which uses CS, GEX, and META characteristics with summation in the fusion layer, achieves the best performance among MLP-based systems. The micro-AUC is 0:877 while the macro-AUC is 0:79. Additionally, we find that when the chemical structural properties are fully used in a complex model like ours, the information gleaned from the GEX dataset is overloaded. With a 13:0% macro-AUC and a 3:1% micro-AUC improvement over the state-of-the-art method, the convolutional neural network that just uses the SMILES string representation of the drug structures outperforms all the other proposed designs. Finally, looking at the confident false positive predictions shows side effects that are not present in the ground truth dataset but are reported in the literature.

## II. LITERATURE SURVEY

The growing demand for effective computational methods in drug safety review led to the development of the deep learning framework DEEPSIDE, which predicts pharmacological side effects. This review of the literature focusses on the key concepts of deep learning methods for pharmaceutical side effect prediction, notably DEEPSIDE:

1. Overview of the Applicability of Drug Side Effect Prediction: Adverse drug responses (ADRs), or side effects, are a significant problem in post-market monitoring and drug development and are the cause of drug withdrawals and patient harm.

Traditional Techniques: In the past, side effect prediction was accomplished by computer methods based on experiments and rules, such as quantitative structure-activity relationship (QSAR) models and statistical learning techniques.

More Complex Models Are Required: Because of the limitations of previous methods, such as their limited scalability and lack of generalisability, deep learning is one of the more sophisticated models that are needed.

2. A summary of deep learning's use in bioinformatics

International Journal of Engineering Research and Science & Technology
ISSN 2319-5991 www.ijerst.com
https://doi.org/10.62643/ijerst.2025.v21.i2.pp756-762
Vol. 21, Issue 2, 2025

Deep Learning Methods: Popular deep learning models in bioinformatics include convolutional neural networks (CNNs), recurrent neural networks (RNNs), and graph neural networks (GNNs). These models are well known for their ability to spot complex patterns and connections in large datasets.

Applications: Deep learning has been used in bioinformatics in a variety of domains, such as genetics, medication creation, and sickness prediction. Combining several biological data types (such as gene expression data and molecular structures) is one important advantage.

3. Architecture of the DEEPSIDE Framework: DEEPSIDE incorporates a variety of data types, such as drug chemical structures, biological properties, and interaction networks, using a multi-modal deep learning architecture.

Input Features: The framework uses a single input feature that combines the chemical fingerprints, side effect labels, and drug-target interactions.

Learning Strategy: The model uses supervised learning for classification tasks (predicting known side effects) and unsupervised learning for feature extraction and representation learning.

Performance and Evaluation Benchmarks: DEEPSIDE is evaluated against a variety of benchmarks, such as different deep learning frameworks and conventional machine learning models. Performance is assessed using metrics such as area under the ROC curve (AUC), recall, accuracy, and precision.

Results: The DEEPSIDE framework is more effective at predicting both common and rare side effects than traditional methods. It efficiently lowers false positives while maintaining high sensitivity.

5. Challenges and Opportunities

Data quantity and quality: The performance of deep learning models like DEEPSIDE is greatly influenced by the quantity and quality of data. Challenges arise from incomplete, noisy, and skewed datasets.

Interpretability: Despite their high projected accuracy, deep learning models are usually "black boxes." In order to better understand the underlying causes of side effects, research is currently being done to make the models more interpretable.

Integration with Clinical Practice: Future studies seek to integrate predictive models into clinical decision support systems (CDSS) for risk assessment and real-time monitoring of patient drug adverse effects.

6. Final thoughts

Impact on the Safety of Drugs: The DEEPSIDE framework is a significant advancement in the field of medication safety. Through the use of deep learning, it enhances pharmaceutical side effect prediction, ultimately resulting in safer medication development and better patient care.

Possibility of Research: The ongoing development of deep learning models holds great promise for improving our understanding of pharmacological side effects and lowering the risks associated with pharmaceutical therapies.

This study review emphasises the value of deep learning in pharmaceutical side effect prediction, particularly when using frameworks such as DEEPSIDE. These models will most likely keep evolving, resulting in more accurate and reliable projections that will allow for safer pharmaceutical procedures.

## III. SYSTEM ANALYSIS

### EXISTING SYSTEM

When two medications interact and one of them influences the pharmacological effects of the other, this is known as a drug-drug interaction (DDI). While negative drug-drug interactions (DDIs) are mostly to blame for adverse pharmaceutical reactions, which may result in drug removal from the market and patient death, positive DDIs have the potential to improve patients' treatment results. Therefore, the development of novel drugs and the treatment of current diseases now depend on the identification of DDIs.

International Journal of Engineering Research and Science & Technology
ISSN 2319-5991 www.ijerst.com
https://doi.org/10.62643/ijerst.2025.v21.i2.pp756-762
Vol. 21, Issue 2, 2025

This paper presents a method based on semi-supervised learning and integrated similarity (DDI-IS-SL) for DDI prediction utilising an existing system. To ascertain how comparable a medication's properties are, DDI-IS-SL integrates drug chemical, biological, and phenotypic data using the cosine similarity technique. The Gaussian Interaction Profile kernel similarity of drugs is also calculated based on known DDIs. The interaction potential scores of the drug-drug pairings are calculated using a semi-supervised learning method called the Regularised Least Squares classifier. When compared to other comparison methodologies, DDI-IS-SL can provide better prediction performance for 5-fold, 10-fold, and de novo drug validation. Additionally, compared to other comparison methods, DDI-IS-SL computes findings on average quicker. Finally, case studies provide further proof of DDI-IS-SL's efficacy in practical contexts.

**Disadvantages**

• Data complexity: Most machine learning models now in use must be able to analyse big and complicated datasets in order to detect a pharmacological adverse effect.

• Data availability: Most machine learning models need a large amount of data to provide accurate predictions. If there is not enough data available, the model's accuracy might deteriorate.

• Inaccurate labelling: The quality of the training data produced from the input dataset determines how accurate the machine learning models that are presently in use are. When data is labelled incorrectly, the model is unable to provide accurate predictions.

**PROPOSED SYSTEM**

Many-layer perceptron (MLP) A series of fully-connected (FC) layers are used in our MLP [22] model to concatenate all of the input vectors. Each FC layer is followed by a batch normalising layer [10]. We use ReLU activation [16] and dropout regularisation [27] with a drop probability of 0:2. The last layer outputs are sent via the sigmoid activation algorithm to get the ADR prediction probabilities. The sum of negative log-probabilities across ADR classes is the loss function, sometimes referred to as the multi-label binary cross-entropy loss (BCE). The architecture for the CS and GEX functions is shown by this system.

ResMLP, or multi-layer perceptron residual The presence of residual connections among the fully-connected layers distinguishes MLP from the residual multi-layer perceptron (ResMLP) architecture. More specifically, before being processed by the next layer, the input of each intermediate layer is added, element by element, to its output. These residual connections have been shown to considerably reduce the vanishing gradient problem [7].

This successfully enables deeper architectures to train more complex and parameter-efficient feature extractors. Neural networks with many modalities (MMNN): Discrete MLP sub-networks, which individually extract features from a particular data modality, are used in this technique. The outputs from these subnetworks are sent to the classification block after fusion. For feature fusion, we investigate two approaches: concatenation and summation. The former concatenates the domain-specific feature vectors to a larger one, whereas the latter does element-wise summing. By definition, summation-based fusion requires domain-specific feature extraction sub-networks to produce vectors of identical sizes. MMNN.Sum and MMNN.Concat are the names of the MMNN networks that are based on concatenation and summing, respectively.

A multitask neural network (MTNN) is used in our multitask learning (MTL) based architecture to take into consideration the side effect classes that are obtained from the ADReCS taxonomy. For this reason, the technique provides MLP sub-network blocks that are both shared and task-

International Journal of Engineering Research and Science & Technology

ISSN 2319-5991 www.ijerst.com

https://doi.org/10.62643/ijerst.2025.v21.i2.pp756-762

Vol. 21, Issue 2, 2025

specific. By using the concatenation of GEX and CS features as input, the shared block generates a joint embedding. Each task-specific sub-network then converts the joint embedding into a vector of binary prediction scores for a set of related side-effect classes.

**Advantages**

- The proposed approach trained and tested datasets using a large number of machine learning classifiers.
- The proposed approach generated convolutional neural networks (CNNs), which are well recognised for providing a powerful technique for automatically learning complex features in vision tasks to find a perfect accuracy on the datasets.

## IV. SYSTEM ARCHITECTURE




## V. SYSTEM IMPLEMENTATION

**MODULES**

**Service Provider**

To access this module, the Service Provider has to provide a working user name and password. After successfully login in, he may do certain actions, such Train & Test Drug Data Sets, See a Bar Chart Showing the Accuracy of Trained and Tested Drug Datasets See the Results for the Accuracy of Trained and Tested Drug Datasets. Examine the many medication side effect prediction types, determine the proportion of each kind, Obtain Predicted Data Sets, See the Results of Every Remote User and Drug Side Effect Prediction Type Ratio

S

**View and Authorize Users**

A list of every user registered in this module is visible to the administrator. Here, the administrator may see user data such as name, email address, and address. They can also authorise users.

**Remote User**

In this module, there are n different users. The user has to register before they can start doing anything. When a user registers, their data is entered into the database. He must log in using his approved user name and password after successfully registering. Once the user has successfully logged in, they may choose the kind of side effect they want to experience, see their profile, and register and log in.

## VI. SCREEN SHOTS

International Journal of Engineering Research and Science & Technology

ISSN 2319-5991 www.ijerst.com

Vol. 21, Issue 2, 2025

https://doi.org/10.62643/ijerst.2025.v21.i2.pp756-762



## VII. CONCLUSION

Pharmaceutical drug development is a time-consuming and difficult procedure. The whole drug development process may be stopped or restarted by unexpected adverse drug reactions (ADRs). Therefore, it is essential to foresee the adverse effects of the medicine before it is designed. Our Deep Side method uses context-related (gene expression) data in addition to the chemical structure to anticipate ADRs while accounting for variables such as dose, time interval, and cell line. By integrating the characteristics of GEX and CS, the proposed MMNN model outperforms models that just use the chemical structure (CS) fingerprints in terms of accuracy. The claimed accuracy is remarkable given that all we are trying to do is forecast the condition-independent side effects. In the end, the SMILES Conv model surpasses all other techniques by applying convolution to the SMILES representation of the drug chemical structure.

## REFERENCES

1. Atias, N., Sharan, R.: An algorithmic framework for predicting side e_ects of drugs. Journal of Computational Biology 18(3), 207{218 (2011)
2. Bresso, E., Grisoni, R., Marchetti, G., Karaboga, A.S., Souchet, M., Devignes, M.D., Sma • _l-Tabbone, M.: Integrative relational machine-learning for understanding drug side-e_ect pro_les. BMC bioinformatics 14(1), 207 (2013)
3. Cai, M.C., Xu, Q., Pan, Y.J., Pan, W., Ji, N., Li, Y.B., Jin, H.J., Liu, K., Ji, Z.L.: Adrecs: an ontology database for aiding standardization and hierarchical classi_cation of adverse drug reaction terms. Nucleic acids research 43(D1), D907{D913 (2014)
4. Dey, S., Luo, H., Fokoue, A., Hu, J., Zhang, P.: Predicting adverse drug reactions through interpretable deep learning framework. BMC Bioinformatics 19 (12 2018). https://doi.org/10.1186/s12859-018-2544-0
5. Dimitri, G.M., Li_o, P.: Drugclust: A machine learning approach for drugs side effects prediction. Computational Biology and Chemistry 68, 204 { 210 (2017). https://doi.org/https://doi.org/10.1016/j.compbiolchem.2017.03.008
6. Groopman, J.E., Itri, L.M.: Chemotherapy-induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute 91(19), 1616{1634 (1999)
7. He, K., Zhang, X., Ren, S., Sun, J.: Deep residual learning for image recognition.

International Journal of Engineering Research and Science & Technology
ISSN 2319-5991 www.ijerst.com
https://doi.org/10.62643/ijerst.2025.v21.i2.pp756-762
Vol. 21, Issue 2, 2025

In: The IEEE Conference on Computer Vision and Pattern Recognition (CVPR) (June 2016)
8. Huang, L.C., Wu, X., Chen, J.Y.: Predicting adverse side e_ects of drugs. BMC genomics 12(5), S11 (2011)
9. Huang, L.C., Wu, X., Chen, J.Y.: Predicting adverse drug reaction pro_les by integrating protein interaction networks with drug structures. Proteomics 13(2), 313{324 (2013)
10. Io_e, S., Szegedy, C.: Batch normalization: Accelerating deep network training by reducing internal covariate shift. arXiv preprint arXiv:1502.03167 (2015)